Trends in novel psychoactive substance use and the impact of Irish legislative efforts

Andrew Mazurek; Margot Bolster

doi:10.33178/SMJ.2019.1.7

Authors

Andrew Mazurek
Margot Bolster

DOI:

https://doi.org/10.33178/SMJ.2019.1.7

Keywords:

novel psychoactive substances, NPS, public health, public health policy

Abstract

Introduction: Novel Psychoactive Substances (NPS) are emerging at increasingly rapid rates, creating unpredictability in drug markets and ineffective drug policies. Ireland has a drug-induced mortality rate greater than three times the European average and the highest rate of NPS use. Given the scarcity of published literature, the National Advisory Committee on Drugs has recommended trends in NPS use be studied in order to facilitate appropriate public health measures.

Objectives: To critically evaluate the published literature on NPS and establish the health risks associated with their use, trends in drug-induced fatalities, and the efficacy of legislative policies in reducing NPS consumption.

Methods: A systematic search of Medline and PubMed was completed based on pre-defined inclusion criteria, and relevant studies were selected for comprehensive analysis.

Results: Clinical experiences of NPS abusers predominantly involved neurological or psychological symptoms, coupled with cardiovascular effects. While the overall prevalence of NPS presentations in Europe remains low, fatal overdoses were primarily attributed to acute overdose and commonly involved ingestion of synthetic cathinones. Legislation in 2010 resulted in decreased rates of recent and problematic NPS use, along with higher rates of negative user experiences. No significant displacement towards established illicit drugs was reported.

Conclusion: This systematic review has demonstrated the current state of knowledge regarding NPS within an Irish context. The trends in NPS prevalence and toxicity are important considerations for the development of effective drug monitoring or enforcement strategies. This knowledge is further relevant for emergency physicians and forensic pathologists in order to make accurate medical assessments.

References

O'Neill C. Novel psychoactive substances: risks and harms. Community Pract. 2014 Aug;87(8):45-7.

Hohmann N, Mikus G, Czock D. Effects and risks associated with novel psychoactive substances: Mislabeling and sale as bath salts, spice, and research chemicals. Dtsch Arztebl Int. 2014 Feb;111 (9):139-47.

Corazza O, Parrott AC, Demetrovics Z. Novel psychoactive substances: Shedding new lights on the ever-changing drug scenario and the associated health risks. Hum Psychopharmacol. 2017 May;32(3):e2616.

Van Hout MC. The Dynamic Landscape of Novel Psychoactive Substance (NPS) Use in Ireland: Results from an Expert Consultation. Int J Ment Health Addiction. 2017 Oct;15(5):985-92.

Ryall G, Butler S. The great Irish head shop controversy. Drugs: Educ Prev Polic. 2011 Aug;18(4):303-11.

Pergolizzi JV, LeQuang JA, Taylor R, Raffa RB. The “Darknet”: The new street for street drugs. J Clin Pharm Ther. 2017 Dec;42 (6):790-2.

European Monitoring Centre for Drugs and Drug Addiction and Europol. Drugs and the darknet: Perspectives for enforcement, research and policy. Luxembourg: EMCDDA–Europol Joint Publications, 2017.

The Gallup Organization. Youth attitudes on drugs. Luxembourg: European Commission, 2011.

European Monitoring Centre for Drugs and Drug Addiction. Ireland: Country Drug Report 2017. Luxembourg: Publications

Office of the European Union, 2017.

Hearne E, Wells J, Van Hout MC. Country report on New Psychoactive Substances in Ireland. Waterford: NPS-Transnational Project, 2017.

Kelleher C, Christie R, Lalor K, Fox J, Bowden M, O'Donnell C. An overview of new psychoactive substances and the outlets supplying them. Dublin: National Advisory Committee on Drugs, 2011.

Martins SS, Sampson L, Cerdá M, Galea S. Worldwide prevalence and trends in unintentional drug overdose: A systematic review of the literature. Am J Public Health. 2015 Nov;105(11):e29–e49.

Tracy DK, Wood DM, Baumeister D. Novel psychoactive substances: types, mechanisms of action, and effects. BMJ. 2017 Jan 25;356:i6848.

Hondebrink L, Nugteren-van Lonkhuyzen JJ, Van Der Gouwe D, Brunt TM. Monitoring new psychoactive substances (NPS) in The Netherlands: data from the drug market and the Poisons Information Centre. Drug Alcohol Depend. 2015 Feb;147:109-15.

Kamijo Y, Takai M, Fujita Y, Sakamoto T. A multicenter retrospective survey of poisoning after consumption of products containing

novel psychoactive substances from 2013 to 2014 in Japan. Am J Drug Alcohol Abuse. 2016 Sep;42(5):513-9.

Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol. 2011 Jul;49(6):499-505.

Giese C, Igoe D, Gibbons Z, Hurley C, Stokes S, McNamara S, et al. Injection of new psychoactive substance snow blow associated with recently acquired HIV infections among homeless people who inject drugs in Dublin, Ireland, 2015. Euro Surveill. 2015;20(40): 30036.

Murray DB, Potts S, Haxton C, Jackson G, Sandilands EA, Ramsey J, et al. 'Ivory wave' toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning. Clin Toxicol. 2012 Feb;50(2):108-13.

Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neuro- transmission in rat brain. Eur J Pharmacol. 2007 Mar 22;559(2-3):132-7.

Burns L, Roxburgh A, Matthews A, Bruno R, Lenton S, Van Buskirk J. The rise of new psychoactive substance use in Australia. Drug Test Anal. 2014 Jul-Aug;6(7-8):846-9.

Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol. 2015 Oct;53(9):893-900.

Elliott S, Evans J. A 3-year review of new psychoactive substances in casework. Forensic Sci Int. 2014 Oct;243:55-60.

Ezaki J, Ro A, Hasegawa M, Kibayashi K. Fatal overdose from synthetic cannabinoids and cathinones in Japan: demographics and autopsy findings. Am J Drug Alcohol Abuse. 2016 Sep;42 (5):520-9.

Barratt MJ, Ferris JA, Winstock AR. Safer scoring? Cryptomarkets, social supply and drug market violence. Int J Drug Policy. 2016 Sep;35:24-31.

Suzuki H, Kawai S, Aizawa T, Kato K, Sunayama S, Okada R, Yamaguchi H. Histological evaluation of coronary plaque in patients with variant angina: relationship between vasospasm and neointimal hyperplasia in primary coronary lesions. J Am Coll Cardiol. 1999 Jan;33 (1):198-205.

Smyth BP, James P, Cullen W, Darker C. "So prohibition can work?" Changes in use of novel psychoactive substances among adolescents attending a drug and alcohol treatment service following a legislative ban. Int J Drug Policy. 2015 Sep;26(9):887-9.

Van Hout MC, Brennan R. Curiosity killed M-Cat: A post-legislative study on mephedrone use in Ireland. Drugs: Educ Prev Pol. 2012;19(2):156-62.

Loeffler G, Craig C. The effect of legal bans on poison control center contacts regarding ‘legal highs’. Addiction. 2013 Jul;108 (7):1348-9.

Wilkins C, Sweetsur P. The impact of the prohibition of benzylpiperazine (BZP) ‘legal highs’ on the prevalence of BZP, new legal highs and other drug use in New Zealand. Drug Alcohol Depend. 2013 Jan 1;127(1-3):72-80.

O'Byrne PM, Kavanagh PV, McNamara SM, Stokes SM. Screening of stimulants including designer drugs in urine using a liquid chromatography tandem mass spectrometry system. J Anal Toxicol. 2013 Mar;37(2):64-73.

Van Hout MC, Bingham T. "A costly turn on": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int J Drug Policy. 2012 May;23 (3):188-97.

EMCDDA. New psychoactive substances in Europe: An update from the EU Early Warning System. March 2015, Luxembourg: Publications Office of the European Union.

European Commission. Youth attitude on drugs. 2011, Brussels: European Commission.

Health Research Board. Drug-related deaths and deaths among drug users in Ireland. 2013 figures from the National Drug-Related Deaths Index. 2015, Dublin: Health Research Board.

Yarema MC, Becker CE. Key concepts in postmortem drug redistribution. Clin Toxicol. 2005:43:235-41.

Han E, Kim E, Hong H, Jeong S, Kim J, In S, Chung H, Lee S. Evaluation of postmortem redistribution phenomena for commonly encountered drugs. Forensic Sci Int. 2012;219:265-71.

McElrath K, O’Neill C. Experiences with mephedrone pre- and post-legislative controls: Perceptions of safety and sources of supply. Int J Drug Policy. 2011;22:120-7.

Measham F, Wood DM, Dargan PI, Moore K. The rise in legal highs: Prevalence and patterns in the use of illegal drugs and first-

and second-generation ‘legal highs’ in South London gay dance clubs. J Subst Use. 2011;16:263-72.

Kavanagh P, Power JD. New psychoactive substances legislation in Ireland – perspectives from academia. Drug Testing Anal. 2014;6(7–8):884-891.